A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta® in healthy male subjects

• Asıl Yazarlar: Yuanyuan Sun (Yazar), Heng Yang (Yazar), Xiaoyan Yang (Yazar), Shuang Yang (Yazar), Can Guo (Yazar), Honghui Chen (Yazar), Chang Cui (Yazar), Yuxia Xiang (Yazar), Guoping Yang (Yazar), Jie Huang (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Purpose: This is the first study to compare the pharmacokinetics, safety and, immunogenicity of QL1209, a biosimilar of Perjeta®.Methods: This study was a randomized, double-blind, parallel-controlled clinical trial evaluating the biosimilarity between QL1209 (specification: 420 mg:14 ml, single use...